Arca
Skip to content
Tools
Tools

SSTR5: Somatostatin receptor type 5

Receptor for somatostatin 28 and to a lesser extent for somatostatin-14.

  • Drugs that act on it: 5
  • Approved: 2
  • In phases 1 to 3: 3
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on SSTR5, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 4
  • Other 1

Approved2

  • Lanreotide
  • Pasireotide

Phase 31

  • Vapreotide

Phase 22

  • Onzigolide
  • Veldoreotide

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Aspireo Pharmaceuticals Limited120%
    • Tiburio Therapeutics120%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Somatostatin receptor 5 agonist.
    LanreotideApprovedIpsenProtein or peptideAgonist12
    PasireotideApprovedNovartis PharmaceuticalsProtein or peptideAgonist8
    VapreotidePhase 3—Protein or peptideAgonist0
    OnzigolidePhase 2Tiburio TherapeuticsOtherAgonist0
    VeldoreotidePhase 2Aspireo Pharmaceuticals LimitedProtein or peptideAgonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
    Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver MetastasesLanreotide—Enrolling by invitationChiyi ChenNov 3, 2026
    Managing Pasireotide-associated Hyperglycaemia in Acromegaly With Ketogenic DietPasireotideNot applicableRecruitingLeiden University Medical CenterOct 8, 2026
    Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine NeoplasmsLanreotidePhase 3RecruitingWashington University School of MedicineSep 25, 2026
    Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort StudyLanreotide—Active, not recruitingWest China HospitalApr 16, 2026
    Effects of Pasireotide Lar Therapy on Bone MetabolismPasireotide—RecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCSSep 18, 2025
    Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenLanreotidePhase 3Active, not recruitingCrinetics Pharmaceuticals Inc.Jul 25, 2025
    Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine TumorsLanreotidePhase 3RecruitingGrupo Espanol de Tumores NeuroendocrinosMar 17, 2025
    Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaLanreotidePhase 3RecruitingSWOG Cancer Research NetworkFeb 4, 2025
    Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETPasireotidePhase 3RecruitingNovartis PharmaceuticalsJan 20, 2025
    Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell TumorPasireotidePhase 2RecruitingUniversity Hospital HeidelbergJun 13, 2024
    A Study of Pasireotide in People With ProlactinomaPasireotidePhase 2RecruitingMemorial Sloan Kettering Cancer CenterMar 6, 2024
    Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaPasireotidePhase 2Active, not recruitingRECORDATI GROUPJul 3, 2023
    Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtientsLanreotidePhase 4RecruitingUniversity Hospital, AntwerpJan 27, 2023
    Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyLanreotidePhase 3Active, not recruitingRayzeBio, Inc.Jul 28, 2022
    Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETPasireotidePhase 3Active, not recruitingAdvanced Accelerator ApplicationsJun 3, 2019
    HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery ComplicationsPasireotidePhase 4Active, not recruitingHelsinki University Central HospitalMay 17, 2016

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Neoplasm
    0.58
    Neuroendocrine neoplasm
    0.58
    Carcinoid syndrome
    0.49
    ACTH-dependent Cushing syndrome
    0.48
    Neuroendocrine carcinoma
    0.46
    Neurodegenerative disease
    0.45
    Digestive system neuroendocrine tumor, grade 1/2
    0.41
    Cancer
    0.40

    Genes and related targets

    Complexes and families that share a gene with this target
    Genes
    SSTR5

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1792, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P35346, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.